R&D | Cutting-edge science and innovative research

R&D

Changing Faces: Board of Director and Advisory Board hires, ...

Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.

News

Which biotechs have raised new VC financing this week?

This week's biggest biotech venture financings include sizeable rounds for Sling Therapeutics, Circle Pharma, and RegCell.

News

Bavarian Nordic has found its new CEO

Six months after Paul Chaplin said he was stepping down as CEO of Bavarian Nordic, the Danish biopharma has named Tarja Stenvall to the role.

News

lightbulb with AI label on white brain inside, against purple background

Novo taps Anthropic's Claude AI for drug discovery

Novo adds Anthropic AI models and Claude Science to its drug discovery toolkit in a bid to become "the world's most AI-driven healthcare company."

News

Legend Biotech names ex-Novartis exec as CEO

Cell therapy developer Legend Biotech has named Ingrid Zhang as its new chief executive, ending its search for new leadership.

News

Pfizer selects once-daily GLP-1 for its obesity push

Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category – but has now decided on a lead candidate.

News

DNA sequencer Element Bio raises $277m to take on Illumina

Element Biosciences’ bid to claim a slice of a DNA sequencing technology market dominated by Illumina has been helped by an impressive $277 million financing round backed by a wide range of

R&D

Partner Content

7th TPD & Induced Proximity Summit

Fast-Track Discovery, Development & Approval of Selective, Safe & Clinically Relevant TACs & Glues for Degradation, Stabilization, & Phosphorylation to Successfully Address

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

R&D

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

Which biotechs have raised new VC financing this week?

This week's biggest biotech venture financings include sizeable rounds for Sling Therapeutics, Circle Pharma, and RegCell.

News

Bavarian Nordic has found its new CEO

Six months after Paul Chaplin said he was stepping down as CEO of Bavarian Nordic, the Danish biopharma has named Tarja Stenvall to the role.

Press Releases

Partner Content

The Evolution Summit Announces September 2026 Program for Cl...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.

Press Releases

Partner Content

Navigating Change: Key Industry Insights at PHARMAP 2026

PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor

Views & Analysis

R&D

Changing Faces: Board of Director and Advisory Board hires, ...

Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.

R&D

Woman in black suit extends hand of welcome to the company

Changing Faces: Pharma and biotech hires, August 2026

August brought another wave of leadership changes across biotech, pharma, and research organisations.

R&D

Female scientists compares test tubes results

Trial complexity is the new normal

When operationalised effectively, RBQM can support earlier risk detection and more targeted quality improvement.

Deep Dive

R&D

Cancer misinformation is a trust problem, not just an inform...

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

Podcasts

R&D

pharmaphorum podcast Episode 272, Dr Harpreet Singh, Precision for Medicine

Understanding Operation Trialblazer, with Dr Harpreet Singh

Dr Harpreet Singh, CMO at Precision for Medicine, brings both an insider and outsider perspective to discussing Operation TRIALBLAZER.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

R&D

CAMP4 on a new class of ASO in gene under expression

CAMP4 Therapeutics CFO Kelly Gold discusses developments in antisense oligonucleotides and CAMP4’s CMP-002 study

Video

R&D

two healthcare professionals looking at chart

Sponsored

Decentralisation by design: Bringing the trial closer withou...

In the third episode of the IQVIA-sponsored PSCS leadership video series, Sinead Callinan, Head of Patient Centred Delivery, discusses DCTs.

R&D

Sponsored

Patient population first: the strategy behind country decisi...

R&D

Sponsored

IQVIA on reducing complexity and workload for clinical trial...

White Papers

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.